New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BSX;STJ;MDT From The Last 14 Days
Check below for free stories on BSX;STJ;MDT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
July 29, 2014
10:00 EDTSTJ, BSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:43 EDTBSXBoston Scientific initiated with a Neutral at Sterne Agee
Target $13.50.
06:43 EDTSTJSt. Jude Medical initiated with a Neutral at Sterne Agee
Subscribe for More Information
July 28, 2014
12:46 EDTMDTMedtronic receives FDA approval for PRESTIGE cervical disc system
Subscribe for More Information
11:07 EDTSTJ, BSX, MDTLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
06:52 EDTMDTFormer official says Obama could limit inversion deals, NY Times reports
President Obama could limit tax inversion deals on his own authority, said Stephen Shay, former deputy assistant Treasury secretary for international tax affairs in the Obama administration, according to The New York Times. A 1969 law gives the president the ability to restrict inversion deals, said Shay, who also worked in the Reagan administration, the newspaper stated. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Alletgan (AGN). Reference Link
06:32 EDTBSXJ&J dispute with Boston Scientific looks set to go to trial, NY Times says
Subscribe for More Information
July 25, 2014
06:30 EDTMDTObama calls on Congress to end inversion deals, NY Times reports
Subscribe for More Information
July 24, 2014
10:56 EDTBSXStocks with call strike movement; NRG BSX
NRG Energy (NRG) January 35 call option implied volatility decreased 2% to 24, NRG Energy Boston Scientific (BSX) January 15 call option implied volatility decreased 2% to 25 according to IVolatility.
08:28 EDTBSXBoston Scientific sees FY operating margin approaching 20%
Subscribe for More Information
08:19 EDTMDTLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
07:04 EDTBSXBoston Scientific raises FY14 adjusted EPS to 79c-83c from 77c-82c
Subscribe for More Information
07:02 EDTBSXBoston Scientific sees Q3 adjusted EPS 18c-20c, consensus 19c
Subscribe for More Information
07:02 EDTBSXBoston Scientific reports Q2 Rhythm Management revenue growth of 7%
Subscribe for More Information
07:01 EDTBSXBoston Scientific reports Q2 adjusted EPS 21c, consensus 19c
Reports Q2 revenue $1.87B, consensus $1.87B
July 23, 2014
17:10 EDTBSXBoston Scientific receives CE Mark for Agent Drug Coated Balloon
Subscribe for More Information
15:30 EDTBSXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
07:45 EDTSTJSt. Jude Medical management to meet with Deutsche Bank
Subscribe for More Information
July 22, 2014
08:25 EDTBSXBoston Scientific risk/reward favorable into Q2 results, says RBC Capital
Subscribe for More Information
08:02 EDTSTJSt. Jude announces FlexAbility Ablation Catheter CE Mark approval, first use
St. Jude Medical CE Mark approval and first use of the FlexAbility Ablation Catheter. Designed with feedback from physician thought-leaders around the world, the FlexAbility catheter combines a unique, irrigated flexible catheter tip with a state-of-the-art handle and catheter design. The next-generation flexible tip technology was designed to reduce complications associated with ablation procedures through its ability to bend and conform to the cardiac anatomy, decreasing the amount of pressure distributed to a patientís heart wall while simultaneously increasing the stability of therapy delivery.
July 21, 2014
16:38 EDTBSXBoston Scientific receives FDA approval for REBEL Platinum Stent system
Subscribe for More Information
08:16 EDTMDTDeutsche Bank analysts hold an analyst/industry conference call
Subscribe for More Information
July 18, 2014
12:51 EDTMDTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
July 16, 2014
10:36 EDTMDTTreasury calls on Congress to halt inversion deals
Subscribe for More Information
08:32 EDTSTJSt. Jude Medical sees revenue growth rate accelerating in 2H
Subscribe for More Information
08:18 EDTSTJ St. Jude Medical sees total Q3 CRM sales $660M-$690M
Sees total FY14 CRM sales $2.81B-$2.85B. Sees Q3 AF product sales $240M-$260M, FY14 AF product sales $1.3B-$1.6B. Sees Q3 cardiovascular product sales $315M-$335M, FY14 cardiovacular product sales $1.36B-$1.39B. Sees Q3 neuromodulation product sales $100M-$110M, sees FY14 neuromodulation product sales $440M-$460M. Sees $15M-$20M related to CardioMEMS product line. Says assumes R&D tax credit will be extended for 2014. Says expects to add $10M-$15M in sales related to NeuroTherm product line in 2014, sees acquisition neutral to EPS in 2014. Sees FY14 gross profit margin 71.5%-72%. Still sees FY14 SG&A as a percentage of net sales to be 33.5%-34%. Sees FY14 effective tax rate 18%-18.5%. Comments made on the Q2 earnings conference call.
07:59 EDTMDTTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical raises FY14 adjusted EPS view to $3.96-$4.01 from $3.95-$4.00
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees Q3 adjusted EPS 95c-97c, consensus 96c
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees FY14 adjusted EPS $3.96-$4.01, consensus $3.99
Sees FY14 revenue $5.64B-$5.76B, consensus $5.7B.
07:31 EDTSTJSt. Jude Medical reports Q2 adjusted EPS $1.02, consensus $1.00
Reports Q2 revenue $1.45B, consensus $1.44B.
07:18 EDTMDTScoliosis Research Society to hold annual meeting
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use